1 Extended spectrum B-lactamase producing E.coli in the community and in hospital Dr Graham Harvey Consultant Microbiologist Director of Infection Prevention.

Slides:



Advertisements
Similar presentations
TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Advertisements

Infection Prevention and Control Jo Lickiss Nurse Consultant Infection Prevention and Control.
Resistant Gram-negative Infections 21 st March 2013 Acute Medicine Study Day Dr Sarah Glover Consultant in Medical Microbiology and Infectious Diseases.
HICC An Infection Control Committee provides a forum for multidisciplinary input and cooperation, and information sharing This committee should include.
Increasing transrectal ultrasound guided prostate biopsy associated infection; is a change in antimicrobial prophylaxis the solution? Authors: Ni Bhuachalla.
Emerging Antimicrobial Resistance in Texas The new ESBLs.
National Changes in Antibiotic Policy R. Andrew Seaton Consultant Physician Lead doctor Antimicrobial Management Team, NHS GG&C.
NICU Outbreaks Nawaf M. Al-Dajani. Disclosure Infection Components Host Organisms Environment.
MANUAL on ALERT ORGANISM SURVEILLANCE
Results (cont.) Figure 3: Gel results checking for digested DNA fragments using the EcoR1 restriction enzyme. (A) Lane 1 shows blue colony obtained from.
Antimicrobial Resistant Enterobacteriaceae
Treatment of urinary tract infections
Epidemiology and Control of Methicillin-Resistant Staphylococcus aureus in hospitals Maria Kapi,MD Registrar of Medical Microbiology Laiko General Hospital.
Prof.Hanan Habib. To eradicate the offending organisms from the urinary bladder and tissues. The main treatment of UTI is by antibiotics.
Acute Oncology Service (Insert relevant service name)
Infection Control- Issues in the Community Dr Yimmy Chow Interim Director and Consultant in Communicable Disease Control NW London Health Protection Team,
Infection Prevention & Control (IPAC) at RCHT Dr Tristan Clark Infectious Diseases physicin and joint DIPC.
Robynn Cheng Leidig, MPH
Pandemic Influenza. Guidance for Pandemic Influenza: Infection Control in Hospitals and Primary Care Settings UK Pandemic Influenza Contingency Plan Operational.
ANTIMICROBIAL RESISTANCE
Ceftazidime resistance in a Salmonella enterica serotype Bareilly in Ireland N.DeLappe, D Morris, C.O’Hare, E.Costello, G.Corbett-Feeney and M.Cormican.
Antimicrobial resistance surveillance in Ireland Results of invasive Escherichia coli infection (blood/CSF) surveillance, 2009 **** Data as of 01/12/2010.
Detection of  -lactamase- mediated resistance David Livermore Health Protection Agency, Colindale, London.
The Antibiotic Sensitivity Test Presented by Marian Mikhail Undergraduate student Biology Major Health and Science Concentration Health and Science Concentration.
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Prescribing Clinicians Comprehensive Antibiogram Toolkit.
National and International Spread of Antimicrobial Resistance: Clones and Genes Professor Alan Johnson, Health Protection Services - HPA.
Treatment of urinary tract infections Prof. Hanan Habib.
Infection control annual report April 2005 to March 2006 Dr Graham Harvey Consultant Microbiologist Director of Infection Prevention & Control.
RESULTS INTRODUCTION METHODS CONCLUSION  Extended spectrum beta-lactamases producing Enterobacteriacae (ESBLPE) have become a major cause of hospital-acquired.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
What’s happening now ? Epidemiology of (carbapenem) resistance Neil Woodford HPA – AMRHAI - Colindale.
Treatment of urinary tract infections
EARS-Net data on Antimicrobial Resistance in Ireland, Q3 2015
European Centre for Disease Prevention and Control
Carbapenemases in practice - lessons learnt from spread in our patch, prophylaxis and first/second line treatments Dr Andrew Dodgson Consultant Microbiologist.
Antimicrobial resistance surveillance in Ireland Results of invasive Klebsiella pneumoniae infection (blood/CSF) surveillance, 2009 **** Data as of 01/12/2010.
MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.
Jane Stockley Chris Catchpole Carole Clive November 2012.
KJO Hospital Infection Control Local 2176/2097 Ross Ibabao/ICCo.
NOROVIRUS OUTBREAK IN A UNIVERSITY TEACHING HOSPITAL O Meara M, O Connor M, Dept of Public Health, Dr. Steevens Hospital Background On March 7th 2006,
Review of Gonorrhoea (GC) Contacts Gay Men’s Health Service 2012 / 2013 Louise PomeroyMick QuinlanSusan Clarke GMHSGMHSSJH / GMHS 9 th November 2013.
Multi-Resistant Gram Negative Microorganisms St Elisabeth Hospital Curacao.
Materials & Methods Objective Extraintestinal pathogenic Escherichia coli in healthy broiler chicken in Italy: a combination of virulence with antibiotic.
How I deal with an outbreak? Prof Bertrand SOUWEINE Medical ICU Clermont-Ferrand France ISICEM March 2009.
Point of Care Diagnostics for Hospital Acquired Infections (HAIs): Health Economics Perspective Detection & Identification of Infectious Agents (DIIA)
Tapasyapreeti Mukhopadhyay, Vrushali Patwardhan, Sarman Singh
Tackling antimicrobial resistance – what is the current situation in Europe? Dr Andrea Ammon, ECDC Director, 27 June 2017, European Parliament.
8th Annual Infection Prevention Conference 23rd June 2011, Harrogate
N°XXXX Rapid detection of extended-spectrum BETA-lactamase producing Enterobacteriaceae from urine using the ESBL NDP test Patrice Nordmann, Laurent Poirel,
Management of Urinary Tract Infections Renal Block
Management of Urinary Tract Infections Renal Block
The Role of the Microbiology Laboratory in AMS programs
Cell wall inhibitor Cephalosporins Dr. Naza M. Ali Lec D
Infection Control Implications of ESBL producing organisms
Antibiotic Susceptibility patterns of culture-positive urine isolates in children under 14 years. Paul Ombuya Laboratory technologist At GCH October 2013.
Clinico-Pathological Conference (CPC) Meet
Antibiotics sensitivity of microorganism causing nosocomial infections
CASE 4 Dr Sani Aliyu Consultant in Microbiology & Infectious Diseases Cambridge University Hospitals.
Dr David Garner Consultant Microbiologist
Antimicrobial Resistance: from Global to Local
Cephalosporin and Cell Wall Synthesis Inhibitors
Neonatal sepsis in Kilifi
The need for new antibiotics
TRAINING PRESENTATION
Control of infections due to extended-spectrum β-lactamase-producing organisms in hospitals and the community  R.E. Warren, G. Harvey, R. Carr, D. Ward,
Tony Crockford & Muhammad Sartaj.
APIC Greater NY Chapter 13 CIC Q&A Review
EARS-Net results 2011 Ole Heuer
New Antibiotic guidelines April 2013
Presentation transcript:

1 Extended spectrum B-lactamase producing E.coli in the community and in hospital Dr Graham Harvey Consultant Microbiologist Director of Infection Prevention & Control Shrewsbury & Telford Hospitals NHS Trust, Shropshire,UK

2 BETA LACTAM RING PENICILLIN BETA LACTAM RING CEPHALOSPORIN BETA LACTAMASES enzymes that inactivate the beta-lactam ring

3 Some beta-lactamases only inactivate a small number of antibiotics e.g. penicillin Others have extended spectrum to all the penicillins and cephalosporins e.g. cefuroxime, ceftriaxone (ESBLs) In addition may also carry resistance to other antibiotics e.g. ciprofloxacin.

4 ESBL Evolution Mid 1980s Variants of TEM and SHV Breakdown 3 rd generation cephalosporins Mainly in hospital Klebsiella Spread world wide

5 Control of a hospital outbreak of ESBL producing Klebsiella peumoniae Aberdeen, Scotland, ITU associated SHV-2 ESBL Increased use of third generation cephalosporins Only sensitive to amikacin & imipenem Environmental contamination (sinks) Improved plumbing ! Multi-disciplinary team approach

6 The rise of CTX-M in Europe Livermore et al JAC (2007) Increasing problem since Mainly in E coli Now over 50 types described 1998 Poland CTX-M 3 & Spain CTX-M France CTX-M Italy CTX-M 1& 15

7 Spread of CTX-M in the UK – First UK isolates (Klebsiella) 2003 onwards – widespread across UK E coli Especially CTX-M-15 Five major clones A-E Also diverse unrelated strains

8 publications/esbl_report_05/default.htm

9 Health Protection Agency report September 2005 Recommendations –Laboratory detection of ESBL producers –Urine samples in Rx failures –Treatment guidelines –Better surveillance –Investigation of animal carriage

10 Health Protection Agency report September 2005 Infection Control of CTX-M –Need for hospital and community guidelines –? Interventions needed –? Endemic in hospitals –Limited data as only recently emerged as a problem

11 Maps of Europe and Shropshire, UK.

12 Shropshire hospital setting 540,000 population. 2 main hospital sites 300 & 520 beds 30 Km apart – 7 intermediate care hospitals : 3 in Wales – 230 bed spinal injury & orthopaedic hospital – 12% single rooms – Minimal neutropenia / transplantation.

13 Start of the Shropshire outbreak Multi-resistant E coli UTIs from May 2003 Mainly community patients Two E.coli strains –Both resistant to quinolones, cephalexin and trimethoprim. –Both sensitive to nitrofurantoin & carbapenems –One strain (strain A) gentamicin resistant.

14

15 E.S.B.L producing E coli in Shropshire 1 Jan 03 to 30 Sep 04 – 364 cases –68% female –mean age 74 years –49% community samples –Diabetes, dementia and malignancy

16 Early Findings Gentamicin sensitive strain initially apparent as a community problem. – samples from GPs and few from psychiatric hospital. –Only 1 nursing home resident. –No apparent serious cases. Gentamicin resistant strain mainly in hospital patients.

17 The evolution of the outbreak – Clinical and epidemiology 1. In-patient cases initially in Telford Hospital Later spread to Shrewsbury Hospital No obvious ward focus (21wards) 90% Hospital contact in past 3 years But in 10% cases no local acute hospital contact.

18

19 Response to the outbreak.1 Community/Hospital outbreak team (Aug 03) Letter to consultants/GPs Sept 03 Restrictive antibiotic reporting Increased use of carbapenems Cases isolated in side rooms

20 Response to the outbreak 2 March 2004 new hospital antibiotic guidelines introduced and strongly promoted

21 Antibiotic Policy changes Nitrofurantoin substituted for quinolones in UTIs Imipenem substituted for quinolones in serious sepsis Ertapenem introduced for ESBL sepsis Gentamicin substituted for cephalosporins in surgical prophylaxis Return to amoxycillin in respiratory tract infections

22

23 Response to the outbreak.3 Increased use of hand gel –Hand gel by each bedside Marking of patient’s electronic records Daily computer search for re-admissions Patient screening (stool & urine) “ESBL management unit” –Cohort ward –Opened May to June 04 –Closed July and August 04 –Re-opened September 04

24 Shropshire ESBL outbreak Aug02-Dec04 Antibiotic policy Isolation ward

25 “Do the sick no harm” The ones that got away –If you do not look you will not find Antibiotic disc problems Gentamicin assays Asymptomatic carriage in the community You are what you eat

26

27 Quinolone R Cephalexin S Urinary E coli Jan 2003 to March ESBL isolates in 370 patients 98 patients had CiproR TriR NitS “LexS” strains ESBL found in 27 of them 68 pats

28 Laboratory testing issues Cefotaxime and ceftazidime or Cefpodoxime +/- clavulanate Manufacture (Oxoid) MHRA Batch to batch variation +/- 40% –10 ug could be 6-14 ug Mixing batches –Test like with like Storage esp clavulanate

29

30 The iceberg effect Opportunistic tests:No.testedPositive% Positive Hospital patients % Community patients 7/11 not hosp assoc.* %

31 CTX-M isolated from chicken meat by country of origin ECCMID 2007

32 Where are we now ?

Total Total Total Total Shrewsbury and Telford NHS Trust New hospital cases of ESBL from May 2003 to March 2007 Ward opened May – June 04 Ward re-opened Sept 04 to Dec 05

34 New Shropshire community cases of ESBL producing E coli from 2002 to 2006

35 Conclusion ESBL vs MRSA –Epidemic strains –Multiple antibiotic resistance –Laboratory tests Detection Chromogenic agar –Silent carriage Screening –Hospital spread Isolation Hand hygiene –Community reservoir

36 And finally… ESBL- 662 MRSA C DIFF Jan 2003 to Dec patients with ESBL, MRSA and/or C DIFF ESBL 662 cases 9.3% C DIFF +ve 25.6% MRSA +ve